➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Indobufen

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Indobufen?

Indobufen is an investigational drug.

There have been 7 clinical trials for Indobufen. The most recent clinical trial was a Phase 3 trial, which was initiated on August 20th 2017.

The most common disease conditions in clinical trials are Coronary Artery Disease, Myocardial Ischemia, and Gastroesophageal Reflux. The leading clinical trial sponsors are Beijing Anzhen Hospital, Ministry of Science and Technology of the People´s Republic of China, and The First Affiliated Hospital with Nanjing Medical University.

There are two hundred and eighty-six US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Indobufen
TitleSponsorPhase
Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart DiseaseHenan Institute of Cardiovascular EpidemiologyN/A
GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet TherapyBeijing Anzhen HospitalPhase 4
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSUREMinistry of Science and Technology of the People´s Republic of ChinaPhase 4

See all Indobufen clinical trials

Clinical Trial Summary for Indobufen

Top disease conditions for Indobufen
Top clinical trial sponsors for Indobufen

See all Indobufen clinical trials

US Patents for Indobufen

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Indobufen   Start Trial Analyte sensor DexCom, Inc. (San Diego, CA)   Start Trial
Indobufen   Start Trial WT1 peptide cancer vaccine composition for transdermal administration NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP)   Start Trial
Indobufen   Start Trial Vaccine composition NITTO DENKO CORPORATION (Osaka, JP)   Start Trial
Indobufen   Start Trial Heterogeneous implantable devices for drug delivery TITAN PHARMACEUTICALS, INC. (South San Francisco, CA)   Start Trial
Indobufen   Start Trial Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CyDex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Indobufen   Start Trial Heterogeneous implantable devices for drug delivery Titan Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Indobufen

Drugname Country Document Number Estimated Expiration Related US Patent
Indobufen Austria 361024 2017-03-04   Start Trial
Indobufen Austria 474219 2017-03-04   Start Trial
Indobufen Austria 480761 2017-03-04   Start Trial
Indobufen Austria 494018 2017-03-04   Start Trial
Indobufen Austria 548971 2017-03-04   Start Trial
Indobufen Australia 2003229330 2017-03-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.